Upper non-variceal gastrointestinal bleeding - review the effectiveness of endoscopic hemostasis methods

Szura, Mirosław; Pasternak, Artur

doi:10.4253/wjge.v7.i13.1088

Cited by 29 publications

(31 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The perceived ease of use, along with its ability to cover a large surface area, makes Hemospray an attractive modality for the treatment of GIB [5]. In addition, it carries a low risk of systemic toxicity, as most of the powder is eliminated in stool and not absorbed via gastrointestinal mucosa.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, it carries a low risk of systemic toxicity, as most of the powder is eliminated in stool and not absorbed via gastrointestinal mucosa. Its effectiveness in achieving hemostasis has been demonstrated in bleeding from numerous etiologies, including peptic ulcers, esophageal varices, therapeutic endoscopic procedures, and those of the lower gastrointestinal tract [3][4][5][6][7]. Additionally, Hemospray has been used successfully in cancer-related bleeding and as a bridge to other, definitive hemostatic modalities [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis

Aziz

Weissman

Mehta

et al. 2020

aog

View full text Add to dashboard Cite

Background Recently, amongst other hemostatic modalities, Hemospray (TC-325) has emerged as an effective method for managing patients with non-variceal upper gastrointestinal bleeding (GIB). We conducted this systematic review and meta-analysis to assess the efficacy of Hemospray in patients with non-variceal upper GIB. Methods Our primary outcomes were clinical and technical success; secondary outcomes were aggregate rebleeding, early rebleeding, delayed rebleeding, refractory bleeding, mortality, and treatment failure. A meta-analysis of proportions was conducted for all reported primary and secondary outcomes. A relative risk meta-analysis was conducted for studies reporting direct comparisons between Hemospray and other hemostatic measures. Results A total of 20 studies with 1280 patients were included in the final analysis. Technical success of Hemospray was seen in 97% of cases (95% confidence interval [CI] 94-98%, I 2 =52.89%) and a significant trend towards increasing technical success was seen during publication years 2011-2019. Clinical success of Hemospray was seen in 91% of cases (95%CI 88-94%, I 2 =47.72%), compared to 87% (95%CI 75-94%, I 2 =0.00%) for other hemostatic measures. The secondary outcomes of aggregate rebleeding, early rebleeding, delayed rebleeding, refractory rebleeding, mortality and treatment failure following the use of Hemospray were seen in 27%, 20%, 9%, 8%, 8%, and 31% of cases, respectively. Conclusion Hemospray is safe, effective and non-inferior to traditional hemostatic measures for the management of non-variceal upper GIB, and can thus be used as an alternative option.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis

Aziz

Weissman

Mehta

et al. 2020

aog

View full text Add to dashboard Cite

show abstract

“…Üst GİS kanamaları tüm GİS kanamalarının yaklaşık %80'ini kapsamaktadır. Acil endoskopik tanı ve tedavilere rağmen hala mortalite oranları %2 ile 10 arasında değişmektedir (3). Yıllık insidansı 103/100.000'dır.…”

Section: Introductionunclassified

“…Ülkemizde üst GİS kanamalarının en sık 3 nedeni peptik ülser hastalığı (duedonum, mide ve anastomoz ülserleri), eroziv gastroduedonit ve özofagus varis kanamalarıdır. GİS kanamalarının yaklaşık %60'ından peptik ülser sorumlu tutulmaktadır (3,5).…”

Section: Introductionunclassified

Demographic Analysis of Non-variceal Upper Gastrointestinal Hemorrhagic Patients

Abaylı¹,

Avcı²,

Avcı³

2019

btd

View full text Add to dashboard Cite

show abstract

“…Although 80% of bleedings in patients spontaneously stop, 20% of them are severe. Although there have been many improvements in modern surgical techniques, intensive care treatments, endoscopic diagnosis and treatments in recent years, mortality is still high and it is around 2-10% [2,3] . The incidence and mortality rates of GIS bleeding increase with age.…”

mentioning

confidence: 99%

The role and importance of antiagregan, anticoagulant drugs in the etiology of upper gastrointestinal system bleeding in elderly

Aktaş¹

2018

Haydarpasa Numune Med J

View full text Add to dashboard Cite

Introduction: In this study, we aimed to determine the role of anticoagulants and antiagregan medications in the etiology and prognosis of the upper gastrointestinal system (GIS) bleeding in elderly patients. Methods: One hundred and eighty-four patients who were admitted to the emergency department with the complaints of upper GIS bleeding between January and December 2016 were evaluated retrospectively regarding the age, gender, complaints, drugs, endoscopy findings, intensive care requirement and mortality. Results: The mean age of 184 patients was 78.3±7.9 years. 112 (60.9%) of them were male and 72 (39.1%) of them were female. 128 (69.6%) of the patients applied with only melena, 32(17.4%) with only hematemesis and 24 (13%) were admitted with both hematemesis and melena. Of the patients, 139 (75.9%) were treated in the internal medicine clinic and 31 (16.8%) were treated in the intensive care unit and 12 (6.5%) were expired. The most commonly used drug was acetylsalicylic acid (ASA) (31.5%) and the most common endoscopic finding was peptic ulcer (55.4%). The mean age of the patients treated in the intensive care unit was 81±7.2years, and 18 (58.1%) of those patients were male. The most common endoscopic finding was peptic ulcer-Forrest 2A (16.2%) and ASA (35.5%) was also the most common drug in that group. The mean age of the 12 patients who were expired was 75.3±7.2 years and 8 (66.7%) of them were male. In 12 patients, the most common endoscopic finding was the peptic ulcer and the most frequent drug was warfarin (33%). Discussion and Conclusion: Antiagregan, anticoagulant, NSAI drugs have significant effects on etiology and prognosis of the upper GIS bleeding in the elderly. Gastroprotective drugs should be added to the treatment of patients using these drugs.

show abstract

Upper non-variceal gastrointestinal bleeding - review the effectiveness of endoscopic hemostasis methods

Cited by 29 publications

References 37 publications

Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis

Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis

Demographic Analysis of Non-variceal Upper Gastrointestinal Hemorrhagic Patients

The role and importance of antiagregan, anticoagulant drugs in the etiology of upper gastrointestinal system bleeding in elderly

Contact Info

Product

Resources

About